News Oligomerix Receives $3.19 Million NIH Commercialization Readiness Pilot Grant for Alzheimer’s Disease Therapy September 15, 2020 By vera This article is sourced from an external publication. Read the original → ← PreviousOligomerix to Present at AAIC 2020 Conference on Small Molecule Inhibitor of Tau Self-AssociationNext →Oligomerix Awarded a $3.19 Million Grant from NIA BioWorld
